Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 study of EV101 alone or in combination with clomiphene and concurrently with temozolomide for the treatment of patients suffering from recurrent or progressive glioblastoma

Next Previous
X
Search
Trial Profile

A phase 1/2 study of EV101 alone or in combination with clomiphene and concurrently with temozolomide for the treatment of patients suffering from recurrent or progressive glioblastoma

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 13 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clomifene (Primary) ; EV 101 (Primary) ; Temozolomide (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 08 Jul 2021 According to an Enveric Biosciences media release, first patient is expected to be enrolled in the fourth quarter of 2021.
    • 08 Jul 2021 According to an Enveric Biosciences media release, the company has received approval from the Israeli Ministry of Health to begin this study. The study will be conducted at the Davidoff Institute of Oncology, Rabin Medical Center, in Israel and Dr. Tali Siegal will be the principal investigator.
    • 22 Jan 2021 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top